1. Home
  2. ARHS vs CRON Comparison

ARHS vs CRON Comparison

Compare ARHS & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arhaus Inc.

ARHS

Arhaus Inc.

HOLD

Current Price

$6.89

Market Cap

956.8M

ML Signal

HOLD

Logo Cronos Group Inc.

CRON

Cronos Group Inc.

HOLD

Current Price

$2.57

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARHS
CRON
Founded
1986
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Other Specialty Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
956.8M
1.0B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
ARHS
CRON
Price
$6.89
$2.57
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$10.78
N/A
AVG Volume (30 Days)
1.2M
854.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$1,379,222,000.00
$146,587,000.00
Revenue This Year
$7.23
$26.34
Revenue Next Year
$7.10
$15.53
P/E Ratio
$14.30
N/A
Revenue Growth
8.51
24.63
52 Week Low
$6.17
$1.69
52 Week High
$12.97
$3.43

Technical Indicators

Market Signals
Indicator
ARHS
CRON
Relative Strength Index (RSI) 46.54 52.25
Support Level $6.17 $2.57
Resistance Level $7.61 $2.61
Average True Range (ATR) 0.27 0.08
MACD 0.13 0.01
Stochastic Oscillator 87.65 64.71

Price Performance

Historical Comparison
ARHS
CRON

About ARHS Arhaus Inc.

Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.

About CRON Cronos Group Inc.

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Share on Social Networks: